Page last updated: 2024-10-18

dalteparin and Cardiac Failure

dalteparin has been researched along with Cardiac Failure in 30 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research Excerpts

ExcerptRelevanceReference
"In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2."5.15Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. ( Goldhaber, SZ; Haas, SK; Kakkar, AK; Knabb, RM; Leizorovicz, A; Merli, G; Weitz, JI, 2011)
"Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI)."3.75Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Aylward, PE; Bergovec, M; Buros, JL; Col, JJ; Gibson, CM; Goodman, SG; Gulba, D; Kunadian, V; Murphy, SA; Pride, YB; Zorkun, C, 2009)
"Therapy to prevent deep venous thrombosis (DVT) and pulmonary embolism remains essential for inpatients, despite short periods of bedrest and hospitalization."2.41Deep venous thrombosis prophylaxis in patients with heart disease. ( Shively, BK, 2001)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (6.67)18.2507
2000's12 (40.00)29.6817
2010's15 (50.00)24.3611
2020's1 (3.33)2.80

Authors

AuthorsStudies
Sandner, SE1
Zimpfer, D1
Zrunek, P1
Steinlechner, B1
Rajek, A1
Schima, H1
Wolner, E1
Wieselthaler, GM1
De Lorenzo, F1
Newberry, D1
Scully, M1
Kadziola, Z1
Dawson, G1
Ranlall, N1
Saba, N1
Noorani, A1
Kashani, S1
Williams, R1
Kakkar, VV1
Shah, Z1
Mastoris, I1
Acharya, P1
Rali, AS1
Mohammed, M1
Sami, F1
Ranka, S1
Wagner, S1
Zanotti, G1
Salerno, CT1
Haglund, NA1
Sauer, AJ1
Ravichandran, AK1
Abicht, T1
Shavadia, J1
Welsh, R1
Gershlick, A1
Zheng, Y1
Huber, K2
Halvorsen, S2
Steg, PG1
Van de Werf, F2
Armstrong, PW2
Chi, G1
Januzzi, JL1
Korjian, S1
Daaboul, Y1
Goldhaber, SZ3
Hernandez, AF1
Hull, RD1
Gold, A1
Cohen, AT5
Harrington, RA1
Gibson, CM2
Gershlick, AH1
Goldstein, P1
Wilcox, R1
Danays, T1
Lambert, Y1
Sulimov, V1
Rosell Ortiz, F1
Ostojic, M1
Welsh, RC1
Carvalho, AC1
Nanas, J1
Arntz, HR1
Grajek, S1
Fresco, C1
Bluhmki, E1
Regelin, A1
Vandenberghe, K1
Bogaerts, K1
Shantsila, E1
Lip, GY1
Mebazaa, A1
Spiro, TE1
Büller, HR1
Haskell, L1
Hu, D1
Hull, R1
Merli, G2
Schellong, SW1
Spyropoulos, AC1
Tapson, VF1
De Sanctis, Y1
Connors, JM1
Borden, M1
Kiernan, MS1
Pham, DT1
DeNofrio, D1
Sylvia, L1
Pride, YB1
Aylward, PE1
Col, JJ1
Goodman, SG1
Gulba, D1
Bergovec, M1
Kunadian, V1
Zorkun, C1
Buros, JL1
Murphy, SA2
Antman, EM2
Gheorghiade, M1
Thyssen, A1
Zolynas, R1
Nadar, VK1
Greenberg, BH1
Mehra, M1
Sun, X1
Tian, H1
Plotnikov, AN1
Burton, P1
Hammerstingl, C1
Omran, H1
Leizorovicz, A3
Kakkar, AK2
Haas, SK1
Knabb, RM1
Weitz, JI1
Cimminiello, C1
Parakh, R1
Wang, C1
Bergmann, JF1
Aispuru, GR1
Clavier, MM1
Cardone, AJ1
Gilberto, DO1
Barousse, AP1
Kleber, FX1
Witt, C1
Vogel, G1
Koppenhagen, K1
Schomaker, U1
Flosbach, CW1
Alikhan, R2
Combe, S2
Samama, MM2
Desjardins, L2
Eldor, A2
Janbon, C2
Olsson, CG2
Turpie, AG2
Shimpo, M1
Morrow, DA1
Weinberg, EO1
Sabatine, MS1
Lee, RT1
Ol'binskaia, LI1
Kolosova, KIu1
Nesterova, SG1
Egorova, TD1
Fedorova, AIu1
Kirsch, M1
Vermes, E1
Boval, B1
Drouet, L1
Loisance, D1
Prifti, E1
Bonacchi, M1
Leacche, M1
Miraldi, F1
Shively, BK1
Tebbe, U1
Schellong, SM1
Haas, S1
Gerlach, HE1
Abletshauser, C1
Sieder, C1
Bramlage, P1
Riess, H1
Haines, ST1
Dager, WE1
Trujillo, TC1
Ferguson, JJ1
Kakkar, R1
Ellis, M1
Fearon, PV1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218]Phase 37,513 participants (Actual)Interventional2012-03-31Completed
STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction[NCT02777580]Phase 4609 participants (Actual)Interventional2017-08-01Active, not recruiting
Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial[NCT04717986]188 participants (Actual)Interventional2021-01-26Completed
Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.[NCT02090712]3,000 participants (Anticipated)Observational [Patient Registry]2010-01-31Enrolling by invitation
Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study[NCT03048032]1,566 participants (Actual)Observational2015-04-30Completed
Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study[NCT00571649]Phase 38,101 participants (Actual)Interventional2007-12-31Completed
Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312]1,024 participants (Actual)Observational2020-03-01Completed
A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.[NCT00457002]Phase 36,758 participants (Actual)Interventional2007-06-30Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]Phase 3105 participants (Anticipated)Interventional2014-04-30Recruiting
International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings[NCT00622648]Phase 48,329 participants (Actual)Interventional2008-01-31Completed
Title: EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients[NCT03243708]90,537 participants (Actual)Interventional2017-12-04Completed
A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412]Phase 33,254 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

mITT Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)

InterventionPercentage of Participants (Number)
Betrixaban1.30
Enoxaparin1.90

mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)

InterventionPercentage of Participants (Number)
Betrixaban1.03
Enoxaparin1.45

mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)

InterventionPercentage of Participants (Number)
Betrixaban4.70
Enoxaparin6.02

mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3

mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)

InterventionPercentage of Participants (Number)
Betrixaban0.94
Enoxaparin1.45

mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)

InterventionPercentage of Participants (Number)
Betrixaban4.43
Enoxaparin5.99

Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3

mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)

InterventionPercentage of Participants (Number)
Betrixaban5.70
Enoxaparin7.18

Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication

Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)

InterventionPercentage of Participants (Number)
Betrixaban0.67
Enoxaparin0.57

Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.4
Enoxaparin5.7

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)8.6
Enoxaparin9.2

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.7
Enoxaparin2.7

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)3.0
Enoxaparin3.1

Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.5
Enoxaparin3.9

Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)9.4
Enoxaparin7.8

Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)

Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin or transfusion of >=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.8
Enoxaparin1.2

Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)

Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin; or transfusion of >= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.1
Enoxaparin1.7

Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.8
Enoxaparin4.5

Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days

All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths. (NCT00571649)
Timeframe: Up to Day 90 + 7 days

,
InterventionPercentage of participants (Number)
Any eventDeath (cardiovascular)Death (other)VTE related death
Enoxaparin6.21.43.71.1
Rivaroxaban (Xarelto, BAY59-7939)6.71.44.31.0

Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

,
InterventionPercentage of participants (Number)
Symptomatic non-fatal PESymptomatic DVT in lower extremityAsymptomatic proximal DVT in lower extremityVTE related death
Enoxaparin0.10.22.40.2
Rivaroxaban (Xarelto, BAY59-7939)0.20.22.40.1

Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

,
InterventionPercentage of participants (Number)
Symptomatic non-fatal PESymptomatic DVT in lower extremityAsymptomatic proximal DVT in lower extremityVTE related death
Enoxaparin0.50.54.41.0
Rivaroxaban (Xarelto, BAY59-7939)0.30.43.50.6

Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90

Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category. (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

,
InterventionPercentage of participants (Number)
Any event-Day 10Ischemic stroke-Day 10Acute MI-Day 10Death (cardiovascular)-Day 10Any event-Day 35Ischemic stroke-Day 35Acute MI-Day 35Death (cardiovascular)-Day 35Any event-Day 90Ischemic stroke-Day 90Acute MI-Day 90Death (cardiovascular)-Day 90
Enoxaparin1.00.30.40.41.60.50.50.82.81.10.71.4
Rivaroxaban (Xarelto, BAY59-7939)1.00.30.50.41.80.50.60.92.80.80.91.4

Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90

Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90 (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

,
InterventionPercentage of participants (Number)
symptomatic VTE (incl. VTE-related death)-Day 10symptomatic VTE (non fatal)-Day 10symptomatic VTE (incl. VTE-related death)-Day 35symptomatic VTE (non fatal)-Day 35symptomatic VTE (incl. VTE-related death)-Day 90symptomatic VTE (non fatal)-Day 90
Enoxaparin0.60.31.40.71.90.9
Rivaroxaban (Xarelto, BAY59-7939)0.70.51.00.61.70.7

Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period

A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.36
Enoxaparin 40 mg2.12

Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.22
Enoxaparin 40 mg0.24

Incidence of Adjudicated PE With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.22
Enoxaparin 40 mg0.24

Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.40
Enoxaparin 40 mg2.50

Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg6.44
Enoxaparin 40 mg6.50

Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.71
Enoxaparin 40 mg2.93

Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period

Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.00
Enoxaparin 40 mg0.15

Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.15
Enoxaparin 40 mg0.49

Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.15
Enoxaparin 40 mg0.37

Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg3.11
Enoxaparin 40 mg3.46

Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants

Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day

InterventionEvent rate (%) (Number)
Apixaban 2.5 mg1.73
Enoxaparin 40 mg1.61

Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants

Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg1.66
Enoxaparin 40 mg1.51

Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period

Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg6.44
Enoxaparin 40 mg6.63

Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.06
Enoxaparin 40 mg0.09

Incidence of All Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of drug to last dose of drug plus 2 days

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg7.73
Enoxaparin 40 mg6.81

Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg7.16
Enoxaparin 40 mg6.83

Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days

InterventionEvent Rate (%): (Number)
Apixaban 2.5 mg2.26
Enoxaparin 40 mg1.90

Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population

VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent rate (%) (Number)
Apixaban 2.5 mg2.71
Enoxaparin 40 mg3.06

Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg2.67
Enoxaparin 40 mg2.08

Incidence of Major Bleeding During the Treatment Period in Treated Participants

Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.47
Enoxaparin 40 mg0.19

Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period

InterventionEvent Rate (%) (Number)
Apixaban 2.5 mg0.40
Enoxaparin 40 mg0.80

Incidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants

Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
InterventionEvent Rate (%) (Number)
MI or stoke (N=3183, 3216)MI (N=3184, 3217)Stroke (N=3183, 3216)Thrombocytopenia (N=3184, 3217)
Apixaban 2.5 mg0.380.220.160.19
Enoxaparin 40 mg0.370.120.250.09

Mean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period

Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
InterventionmmHg (Mean)
Day of Discharge from Hospital (N=1607, 1625)Day 30 of Treatment + 2 (N=2227,2301)
Apixaban 2.5 mg-1.00.0
Enoxaparin 40 mg-0.4-0.5

Mean Change From Baseline in Heart Rate in Treated Participants

Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionbpm (Mean)
Hospital Discharge (N=1606,1622)Day 30 of treatment (N=2225,2299)
Apixaban 2.5 mg-5.4-4.0
Enoxaparin 40 mg-5.1-4.3

Mean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period

Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
InterventionmmHg (Mean)
Discharge from Hospital (N=1607, 1625)Day 30 of Treatment + 2 (N=2227, 2301)
Apixaban 2.5 mg-3.0-2.3
Enoxaparin 40 mg-2.4-2.9

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants

Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths. (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)

,
Interventionparticipants (Number)
AEsSAEsBleeding AEsDiscontinuations Due to AEDeaths
Apixaban 2.5 mg1871611244290131
Enoxaparin 40 mg1910601221262133

Number of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements

Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)

,
Interventionparticipants (Number)
Neurologic AEsNeurologic SAEsLiver-related AEsLiver-related SAEs
Apixaban 2.5 mg4551279
Enoxaparin 40 mg42114212

Number of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants

Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of >3*Upper Limit of Normal (ULN) for ALT and AST and elevation of >2*ULN for Bilirubin. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
AST Elevation >3*ULN (N=2831, 2863)ALT Elevation >3*ULN (N=2827, 2861)AST + ALT >3*ULN on same date (N= 2827, 2861)TBili >2*ULN (N= 2853, 2884)ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855)ALT>3*ULN + TBili >2*ULN (N=2817, 2853)
Apixaban 2.5 mg2322141320
Enoxaparin 40 mg2832131422

Number of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants

Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if PreRx < LLN then use < 0.75* PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if PreRx < LLN then use < 0.75*PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if PreRx < LLN then use < 0.95*PreRx or > ULN if PreRx > ULN then use > 1.05*PreRx or < LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Calcium < 0.8*LLN (N=2861, 2893)Calcium > 1.2*ULN (N=2861, 2893)Chloride < 0.9*LLN (N=2861, 2886)Chloride > 1.1*ULN (N=2861, 2886)Bicarbonate < 0.75*LLN (N=2831, 2855)Bicarbonate > 1.25*ULN (N=2831, 2855)Potassium < 0.9*LLN (N=2851, 2878)Potassium > 1.1*ULN (N=2851, 2878)Sodium < 0.95*LLN (N=2862, 2888)Sodium > 1.05*ULN (N=2862, 2888)
Apixaban 2.5 mg632555661140239
Enoxaparin 40 mg832516458137256

Number of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants

Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if PreRx < LLN then use 0.9* PreRx or > ULN if PreRx > ULN then use 1.1 *PreRx or 1.5* ULN, or if PreRx > ULN then use > 2 *PreRx. Glucose Fasting: <0.9*LLN or > 1.5*ULN or if PreRx < LLN then use < 0.8*PreRx or > ULN, if PreRx > ULN then use >2.0*PreRx. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) ± 2days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Glucose Fasting <0.9*LLN (N=284,287)Glucose Fasting > 1.5*ULN (N=284,287)Total Protein < 0.9 *LLN (N=2864, 2890)Total Protein > 1.1*ULN (N=2864, 2890)Creatine kinase >5*ULN U/L(N=2856, 2888)Uric acid > 1.5* ULN (N=2862, 2889)
Apixaban 2.5 mg5397816847
Enoxaparin 40 mg3305181044

Number of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants

Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: >2 g/dL decrease compared to PreRx value or value <=8 g/dL; Hematocrit: <0.75*PreRx; Erythrocytes: <0.75*PreRx c/µL; Leukocytes: <0.75*LLN or > 1.25*ULN, if PreRx ULN, if PreRx >ULN then use >1.2*PreRx or < LLN; Platelet count: < 100*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.75*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes > 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL or > 7.5*10^3 c/ µL. Samples were obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Hemoglobin >2 g/dL decrease (N=2835, 2871)Hematocrit <0.75*PreRx (N=2688, 2722)Platelet Count < 100*10^9 c/L (N=2761, 2799)Erythrocytes <0.75*PreRx c/µL (N=2697, 2730)Leukocytes <0.75*LLN (N= 2835, 2869)Leukocytes > 1.25*ULN (N=2835, 2869)Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24)Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24)Abs Monocytes > 2000/MM^3 (N= 19, 25)
Apixaban 2.5 mg1332392864331141
Enoxaparin 40 mg981771655283120

Number of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants

Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days

,
Interventionparticipants (Number)
Alkaline phosphatase U/L > 2*ULN(N=2866, 2895)ALT U/L > 3*ULN (N=2827, 2861)AST U/L > 3*ULN (N=2831, 2863)Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821)Bilirubin Total mg/dL > 2*ULN (N=2853, 2884)BUN mg/dL > 1.5*ULN (N=2864, 2891)Creatinine mg/dL > 1.5*ULN (N=2862, 2892)
Apixaban 2.5 mg35232412317194150
Enoxaparin 40 mg47332910615188156

Reviews

3 reviews available for dalteparin and Cardiac Failure

ArticleYear
Discoveries in thrombosis care for medical patients.
    Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3

    Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Critical Care; Drug Costs; Enoxaparin; Fibrinolytic

2002
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
    Kardiologiia, 2005, Volume: 45, Issue:12

    Topics: Anticoagulants; Azetidines; Benzylamines; Dalteparin; Double-Blind Method; Enoxaparin; Fibrinolytic

2005
Deep venous thrombosis prophylaxis in patients with heart disease.
    Current cardiology reports, 2001, Volume: 3, Issue:1

    Topics: Angina, Unstable; Anticoagulants; Critical Care; Enoxaparin; Heart Failure; Heparin; Humans; Myocard

2001

Trials

11 trials available for dalteparin and Cardiac Failure

ArticleYear
Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation.
    Artificial organs, 2008, Volume: 32, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Heart Failure; Heart-Assist Devices; Heparin; Heparin,

2008
Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure.
    American heart journal, 2002, Volume: 143, Issue:4

    Topics: Aged; Aged, 80 and over; Biomarkers; Blood Coagulation Disorders; Double-Blind Method; Factor VII; F

2002
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.
    Journal of thrombosis and thrombolysis, 2017, Volume: 44, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Benzamides; Enoxaparin; Female; Heart Failure; Hospitalizati

2017
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2013, Apr-11, Volume: 368, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination;

2013
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2011, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Biomarkers; Chronic Disease; Doubl

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Low-molecular-weight heparin and mortality in acutely ill medical patients.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method;

2011
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    American heart journal, 2003, Volume: 145, Issue:4

    Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; H

2003
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Dose-Response Relationship, Drug; Double-B

2003
Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.
    American heart journal, 2011, Volume: 161, Issue:2

    Topics: Aged; Anticoagulants; Double-Blind Method; Female; Heart Failure; Heparin; Heparin, Low-Molecular-We

2011

Other Studies

16 other studies available for dalteparin and Cardiac Failure

ArticleYear
The use of enoxaparin as bridge to therapeutic INR after LVAD implantation.
    Journal of cardiothoracic surgery, 2020, Nov-14, Volume: 15, Issue:1

    Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Heart-Assist Device

2020
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016
Thrombotic complications in heart failure: an underappreciated challenge.
    Circulation, 2014, Jul-29, Volume: 130, Issue:5

    Topics: Enoxaparin; Female; Heart Failure; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromb

2014
Anticoagulation management of left ventricular assist devices.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Heart Failure; Heart Transplantation; Heart Ventricles;

2015
Bridging with half-therapeutic dose enoxaparin in outpatients with left ventricular assist devices and sub-therapeutic international normalized ratios.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2015, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Feasib

2015
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
    Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C

2009
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail

2011
Thrombotic biomarkers and left ventricle characteristics as short-term predictors of thrombotic events in patients hospitalized for acute decompensated heart failure.
    European journal of internal medicine, 2012, Volume: 23, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Echocardiography; Enoxaparin; Female; Fibrin Fi

2012
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.
    Circulation, 2004, May-11, Volume: 109, Issue:18

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Comorbidity; Drug

2004
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.
    Archives of internal medicine, 2004, May-10, Volume: 164, Issue:9

    Topics: Acute Disease; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heart Failure; Hospitalization

2004
[Four years of circulatory support with the INCOR axial pump from Berlin Heart].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:11

    Topics: Clopidogrel; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Heart Failure; Heart-Assist Devic

2007
[Prevention of embolism in severely ill internal medicine patients. In heart failure it is better to use low molecular weight heparin].
    MMW Fortschritte der Medizin, 1999, Nov-18, Volume: 141, Issue:46

    Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Germany; Heart Failure; Humans; Thromboembolis

1999
Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2000, Volume: 17, Issue:6

    Topics: Adult; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Cardiac Catheterization; Cardiopulmo

2000
Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, May-15, Volume: 67, Issue:10 Suppl 6

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Bariatric Surgery; Colonic Neoplasms; Daltepar

2010
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
    Circulation, 1999, Aug-10, Volume: 100, Issue:6

    Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo

1999
Compartment syndrome of the thigh as a complication of anticoagulant therapy in a patient with a left ventricular assist device (Berlin Heart).
    General thoracic and cardiovascular surgery, 2010, Volume: 58, Issue:9

    Topics: Anticoagulants; Compartment Syndromes; Heart Failure; Heart-Assist Devices; Hemorrhage; Heparin, Low

2010